Unmasking MASH and MASLD

Create Account

Availability

On-Demand

5 Courses

Access expires on Oct 26, 2026

Cost

$0.00

Credit Offered

1 AOA Category 1-A Credit

1 AMA PRA Category 1 Credit

OVERVIEW
In recent years, the field of liver disease has undergone a major shift. A global expert consensus in 2023 redefined Non-Alcoholic Fatty Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH) as Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH). This understanding of the strong links between liver health, metabolic dysfunction, type 2 diabetes, and obesity. A new related category, MetALD (Metabolic dysfunction and Alcohol-associated Steatotic Liver Disease), highlights the need for tailored management strategies for specific patient populations. Why does this matter for you as a clinician? Because MASLD and MASH are highly prevalent in primary care populations, and early recognition and intervention can dramatically improve outcomes. With new nomenclature, evolving guidelines, and emerging therapies, staying current is essential to delivering optimal patient care. Recognizing this, the American Association for the Study of Liver Diseases (AASLD) has identified MASLD/MASH as a top educational priority.

OBJECTIVES

Review the epidemiology and clinical significance of MASLD/MASH
Apply best practices in diagnosis and testing, including non-invasive tools and care pathways
Outline treatment strategies, from lifestyle management to emerging therapies
Explore the latest research and how it shapes practice guidelines

Expiration Date: October 26, 2026

ACOFP designates this enduring activity series for a maximum of 1.0 AOA Category 1-A Credit and will report continuing medical education (CME) credits commensurate with the physician’s participation in this program.

ACOFP designates this enduring activity series for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should only claim the credit commensurate with the extent of their participation in the activity.

This activity is approved for 1.0 enduring AAFP Prescribed Credit.

This activity is supported by independent educational grants from Boehringer-Ingelheim Pharmaceuticals, Inc., and Novo Nordisk, Inc.